Terms: = Gastric cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
148 results:
1. Targeting PI3K/AKT/mTOR and MAPK Signaling Pathways in gastric cancer.
Morgos DT; Stefani C; Miricescu D; Greabu M; Stanciu S; Nica S; Stanescu-Spinu II; Balan DG; Balcangiu-Stroescu AE; Coculescu EC; Georgescu DE; Nica RI
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339127
[TBL] [Abstract] [Full Text] [Related]
2. Incidence of type 2 diabetes after gastric by-pass surgery in a Swedish controlled cohort study.
Jamaly S; Lundberg CE; Adiels M; Lagergren J; Björck L; Rosengren A
Obes Res Clin Pract; 2024; 18(1):15-20. PubMed ID: 38199930
[TBL] [Abstract] [Full Text] [Related]
3. Active ingredients Isorhamnetin of Croci Srigma inhibit stomach adenocarcinomas progression by MAPK/mTOR signaling pathway.
Shi XF; Yu Q; Wang KB; Fu YD; Zhang S; Liao ZY; Li Y; Cai T
Sci Rep; 2023 Aug; 13(1):12607. PubMed ID: 37537191
[TBL] [Abstract] [Full Text] [Related]
4. Clinicopathological Characteristics of NRG1 Fusion-Positive Solid Tumors in Korean Patients.
Cha YJ; Lee C; Joo B; Kim KA; Lee CK; Shim HS
Cancer Res Treat; 2023 Oct; 55(4):1087-1095. PubMed ID: 37321274
[TBL] [Abstract] [Full Text] [Related]
5. AMT-562, a Novel her3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for her3-expressing Tumors.
Weng W; Meng T; Pu J; Ma L; Shen Y; Wang Z; Pan R; Wang M; Chen C; Wang L; Zhang J; Zhou B; Shao S; Qian Y; Liu S; Hu W; Meng X
Mol Cancer Ther; 2023 Sep; 22(9):1013-1027. PubMed ID: 37302522
[TBL] [Abstract] [Full Text] [Related]
6. Nanoplatform-based analysis for the detection of her3 and HER4 for gastric cancer diagnosis.
Gheorghe DC; Stefan-Van Staden RI; Ilie-Mihai RM; Sfirloaga P
Nanotechnology; 2023 Jun; 34(34):. PubMed ID: 37253333
[TBL] [Abstract] [Full Text] [Related]
7. Genetic and immune microenvironment characterization of HER2-positive gastric cancer: Their association with response to trastuzumab-based treatment.
Kwon HJ; Park Y; Nam SK; Kang E; Kim KK; Jeong I; Kwak Y; Yoon J; Kim TY; Lee KW; Oh DY; Im SA; Kong SH; Park DJ; Lee HJ; Kim HH; Yang HK; Lee HS
Cancer Med; 2023 May; 12(9):10371-10384. PubMed ID: 36916290
[TBL] [Abstract] [Full Text] [Related]
8. Further prognostic stratification of intestinal type of gastric adenocarcinoma by CDX2 expression pattern.
Hao Y; Liu BL; Liang Y; Xiong Y; Polydorides AD; Ward S
Hum Pathol; 2023 Jan; 131():61-67. PubMed ID: 36403867
[TBL] [Abstract] [Full Text] [Related]
9. The role of proximal gastrectomy in gastric cancer.
Hirata Y; Kim HI; Grotz TE; Matsuda S; Badgwell BD; Ikoma N
Chin Clin Oncol; 2022 Oct; 11(5):39. PubMed ID: 36336898
[TBL] [Abstract] [Full Text] [Related]
10. her3 PET Imaging Predicts Response to Pan Receptor Tyrosine Kinase Inhibition Therapy in gastric cancer.
Esfahani SA; de Aguiar Ferreira C; Rotile NJ; Ataeinia B; Krishna S; Catalano OA; Caravan P; Yen YF; Heidari P; Mahmood U
Mol Imaging Biol; 2023 Apr; 25(2):353-362. PubMed ID: 35962301
[TBL] [Abstract] [Full Text] [Related]
11. Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma.
Masaki Y; Akutsu N; Adachi Y; Ishigami K; Iwata N; Endo T; Ishii Y; Sasaki Y; Nagayama M; Kimura Y; Nakase H
Clin J Gastroenterol; 2022 Aug; 15(4):809-817. PubMed ID: 35699889
[TBL] [Abstract] [Full Text] [Related]
12. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review.
Blangé D; Stroes CI; Derks S; Bijlsma MF; van Laarhoven HWM
Cancer Treat Rev; 2022 Jul; 108():102418. PubMed ID: 35689885
[TBL] [Abstract] [Full Text] [Related]
13. A Phase 2 Trial of Afatinib in Patients with Solid Tumors that Harbor Genomic Aberrations in the HER family: The MOBILITY3 Basket Study.
Salawu A; Hansen AR; Spreafico A; Al-Ezzi E; Webster S; Bedard PL; Doi J; Wang L; Siu LL; Abdul Razak AR
Target Oncol; 2022 May; 17(3):271-281. PubMed ID: 35635640
[TBL] [Abstract] [Full Text] [Related]
14. The HER family as therapeutic targets in colorectal cancer.
Ye P; Wang Y; Li R; Chen W; Wan L; Cai P
Crit Rev Oncol Hematol; 2022 Jun; 174():103681. PubMed ID: 35462030
[TBL] [Abstract] [Full Text] [Related]
15. Surgical treatment of obesity and excess risk of developing heart failure in a controlled cohort study.
Lundberg CE; Jamaly S; Adiels M; Lagergren J; Svensson CJ; Björck L; Rosengren A
ESC Heart Fail; 2022 Jun; 9(3):1844-1852. PubMed ID: 35274493
[TBL] [Abstract] [Full Text] [Related]
16. Met-her3 crosstalk supports proliferation via MPZL3 in MET-amplified cancer cells.
Stern YE; Al-Ghabkari A; Monast A; Fiset B; Aboualizadeh F; Yao Z; Stagljar I; Walsh LA; Duhamel S; Park M
Cell Mol Life Sci; 2022 Mar; 79(3):178. PubMed ID: 35249128
[TBL] [Abstract] [Full Text] [Related]
17. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract] [Full Text] [Related]
18. A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast cancer.
Cruz RGB; Madden SF; Brennan K; Hopkins AM
Cells; 2022 Feb; 11(4):. PubMed ID: 35203384
[TBL] [Abstract] [Full Text] [Related]
19. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
20. Efficacy of targeted therapy in patients with HER2-positive non-small cell lung cancer: A systematic review and meta-analysis.
Wu HX; Zhuo KQ; Wang K
Br J Clin Pharmacol; 2022 May; 88(5):2019-2034. PubMed ID: 34820879
[TBL] [Abstract] [Full Text] [Related]
[Next]
